Syngene International, a subsidiary of Indian biopharmaceutical company Biocon, has implemented Genedata’s Genedata Screener as its primary analysis tool for in vitro screening assays.
The India-based contract research, development, and manufacturing organisation (CRDMO) is using the tool for in-vitro biochemical and cell-based screening assay data analysis, with initial support from the Genedata team.
Syngene International chief scientific officer Jayashree Aiyar said: “The platform is easy to use so it took minimal effort for our scientists to become proficient. With Genedata in place, it’s easier to work with our partners and our analysis is much faster and more robust.”
Syngene International discovery biology director Anuradha Ramanathan said: “We could begin using it quickly, thanks to support from the Genedata Team. After a brief, guided initial setup we could instantly centralise and easily manage our data.
“With multiple technologies, partners, software, and users, managing our data pipeline is critical to deliver for our partners. Genedata centralises all of that into one place and makes it much easier to manage.”
Established in 1997, Genedata is a Switzerland-based enterprise software solutions provider focused on biopharmaceutical research and development (R&D).
The company developed the Genedata Screener to bring the data management and analysis for all screening and assay development operations into one platform.
The assay analytics tool validates raw data and the quality of assay results, consolidating information across the enterprise and external collaborators.
Genedata president Othmar Pfannes said: “We are pleased that Syngene has adopted Genedata Screener to facilitate easier data exchange with their partners.
“We see a way to dramatically accelerate biopharma R&D by supporting CRDMOs and their partners in the biopharma industry in harmonising data analytical workflows and streamlining the collaboration between them.”
